Last reviewed · How we verify
Tuazole (METHAQUALONE)
METHAQUALONE (Tuazole) is a marketed drug that modulates the GABA A receptor, primarily used for treating conditions involving sleep and anxiety. Its key strength lies in its mechanism of action, which differentiates it from off-patent competitors like scopolamine and ethchlorvynol. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | METHAQUALONE |
|---|---|
| Drug class | methaqualone |
| Target | GABA-A receptor alpha-6/beta-2, GABA A receptor alpha-2/beta-2/gamma-2, GABA A receptor alpha-3/beta-2/gamma-2 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study (NA)
- Combined Upper-airway and Breathing Control Therapies for Obstructive Sleep Apnea (PHASE2)
- Transmission of Tuberculosis Among Illicit Drug Use Linkages
- Trial on Oral Appliance Design for Improving Upper Airway Function and Sleep Quality (NA)
- Evaluation of the Cardiovascular Effects of the MAS in the Treatment of Obstructive Sleep Apnea (NA)
- MRA Therapy Versus CPAP Therapy in Moderate OSAS (NA)
- The Effects of Oral Appliance Therapy on Masseter Muscle Activity in Obstructive Sleep Apnea (NA)
- Effect of Oral Appliance Therapy on Glucose Levels in Patients With T2DM and OSA: A Pilot Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |